Telaprevir

特拉匹韦

Report date: 2026/03/20 20:03:07
NMEFirst In Class

Base Information

Drug NameTelaprevir
Drug Alias Name特拉泼维telaprevirum替拉瑞韦特拉瑞韦Incivo +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsOpioid-Related DisordersKidney DiseasesHepatic Insufficiency +[7] 
Global Approved IndicationsHepatitis C
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2011/05/23
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesVertex Pharmaceuticals Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyMitsubishi Tanabe Pharma
Inactive CompaniesWeill Medical College of Cornell UniversityTibotec Pharmaceuticals, IrelandMitsubishi Tanabe Pharma Corp +[7] 
Active IndicationsHepatitis C
Inactive IndicationsOpioid-Related DisordersKidney DiseasesHepatic Insufficiency +[6] 

Other Information

ATC CodeJ05AP02
Related LinksWikipediaDrugBankKEGG